NASDAQ:ALEC Alector (ALEC) Stock Price, News & Analysis → The World’s Richest Man Blindsided by AI (From Banyan Hill Publishing) (Ad) Free ALEC Stock Alerts $5.28 -0.11 (-2.04%) (As of 01:15 PM ET) Add Compare Share Share Today's Range$5.25▼$5.6350-Day Range$4.81▼$6.8552-Week Range$3.66▼$9.06Volume167,200 shsAverage Volume642,314 shsMarket Capitalization$508.94 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Alector alerts: Email Address Alector MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside165.2% Upside$14.00 Price TargetShort InterestBearish10.20% of Float Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment0.41Based on 14 Articles This WeekInsider TradingSelling Shares$211,434 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.95) to ($2.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.45 out of 5 starsMedical Sector873rd out of 2,771 stocksBiological Products, Except Diagnostic Industry106th out of 462 stocks 3.3 Analyst's Opinion Consensus RatingAlector has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageAlector has only been the subject of 2 research reports in the past 90 days.Read more about Alector's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.20% of the float of Alector has been sold short.Short Interest Ratio / Days to CoverAlector has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.Change versus previous monthShort interest in Alector has recently increased by 9.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlector does not currently pay a dividend.Dividend GrowthAlector does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlector has received a 70.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for diseases with neurocognitive impairment" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Alector is -0.92. Previous Next 1.9 News and Social Media Coverage News SentimentAlector has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Alector this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ALEC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $211,434.00 in company stock.Percentage Held by Insiders14.00% of the stock of Alector is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.83% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alector's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alector are expected to decrease in the coming year, from ($1.95) to ($2.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alector is -3.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alector is -3.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlector has a P/B Ratio of 3.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alector's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingLook Who Fired the World’s Richest ManThis company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S. And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman.Get the full story here. About Alector Stock (NASDAQ:ALEC)Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Read More ALEC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALEC Stock News HeadlinesMay 12 at 4:34 AM | americanbankingnews.comHC Wainwright Trims Alector (NASDAQ:ALEC) Target Price to $35.00May 12 at 4:34 AM | americanbankingnews.comCantor Fitzgerald Reaffirms "Overweight" Rating for Alector (NASDAQ:ALEC)May 9, 2024 | globenewswire.comAlector to Participate in Upcoming Healthcare ConferencesMay 9, 2024 | investorplace.comALEC Stock Earnings: Alector Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | sfgate.comAlector: Q1 Earnings SnapshotMay 8, 2024 | americanbankingnews.comAlector, Inc. (NASDAQ:ALEC) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 30, 2024 | finance.yahoo.comAlector, Inc. (ALEC)April 27, 2024 | nasdaq.comAlector, Inc. Common Stock (ALEC)April 19, 2024 | msn.comAlzheimer's Agitation Relapse Delayed With Dextromethorphan-BupropionApril 11, 2024 | finance.yahoo.comThe past five years for Alector (NASDAQ:ALEC) investors has not been profitableMarch 17, 2024 | finance.yahoo.comALEC Jan 2025 7.500 callMarch 16, 2024 | finance.yahoo.comALEC Oct 2024 7.500 putMarch 7, 2024 | markets.businessinsider.comAlector’s Clinical Progress and Financial Health Anchor Buy RecommendationMarch 1, 2024 | finance.yahoo.comThe Alector, Inc. (NASDAQ:ALEC) Full-Year Results Are Out And Analysts Have Published New ForecastsFebruary 28, 2024 | markets.businessinsider.comAlector: Cautious Hold Rating Ahead of Key Clinical Trial Milestones and Financial AssessmentFebruary 28, 2024 | markets.businessinsider.comOptimistic Buy Rating for Alector’s AL002 Based on Promising Alzheimer’s Disease Trial Biomarkers and TREM2 Signaling EfficacyFebruary 28, 2024 | finance.yahoo.comAlector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | globenewswire.comAlector to Participate in Upcoming Healthcare ConferencesFebruary 28, 2024 | markets.businessinsider.comTD Cowen Sticks to Their Buy Rating for Alector (ALEC)February 27, 2024 | benzinga.comRecap: Alector Q4 EarningsFebruary 27, 2024 | finance.yahoo.comAlector Inc (ALEC) Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | globenewswire.comAlector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 26, 2024 | benzinga.comEarnings Outlook For AlectorFebruary 26, 2024 | markets.businessinsider.comHere's what to expect from Alector's earningsFebruary 20, 2024 | finance.yahoo.comAlector to Host Fourth Quarter and Full-Year 2023 Earnings CallSee More Headlines Receive ALEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/14/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ALEC CUSIPN/A CIK1653087 Webwww.alector.com Phone(415) 231-5660FaxN/AEmployees244Year Founded2013Price Target and Rating Average Stock Price Target$14.00 High Stock Price Target$35.00 Low Stock Price Target$4.00 Potential Upside/Downside+165.2%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-130,390,000.00 Net Margins-125.11% Pretax Margin-120.63% Return on Equity-71.80% Return on Assets-18.28% Debt Debt-to-Equity RatioN/A Current Ratio3.53 Quick Ratio3.53 Sales & Book Value Annual Sales$97.06 million Price / Sales5.24 Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book3.74Miscellaneous Outstanding Shares96,390,000Free Float82,891,000Market Cap$508.94 million OptionableOptionable Beta0.82 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Arnon Rosenthal Ph.D. (Age 68)Co-Founder, CEO & Director Comp: $1.02MDr. Sara Kenkare-Mitra Ph.D. (Age 56)President and Head of Research & Development Comp: $1.19MDr. Marc Grasso M.D. (Age 50)CFO, Principal Financial Officer & Principal Accounting Officer Comp: $738.05kDr. Gary Romano M.D. (Age 62)Ph.D., Chief Medical Officer Comp: $602.98kMr. Peter Heutink Ph.D.Chief Scientific OfficerKatie HoganSenior Director of Corporate Communication & Investor RelationsMs. Danielle Pasqualone J.D.Ph.D., General CounselMs. Clare Hunt M.B.A.Chief People OfficerMs. Kristina Cutter M.P.H.Chief Regulatory, Pharmacovigilance, & Quality Assurance OfficerMs. Virginia DeJesus-Rueff M.B.A.Chief of Staff & Head of StrategyMore ExecutivesKey CompetitorsProKidneyNASDAQ:PROKValnevaNASDAQ:VALNAllogene TherapeuticsNASDAQ:ALLOVoyager TherapeuticsNASDAQ:VYGRHumacyteNASDAQ:HUMAView All CompetitorsInsiders & InstitutionsAmerican International Group Inc.Bought 4,105 shares on 5/14/2024Ownership: 0.037%Vanguard Group Inc.Bought 526,037 shares on 5/10/2024Ownership: 5.097%Acadian Asset Management LLCBought 301,936 shares on 5/10/2024Ownership: 0.461%Russell Investments Group Ltd.Bought 7,066 shares on 5/8/2024Ownership: 0.081%ProShare Advisors LLCBought 3,827 shares on 5/8/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions ALEC Stock Analysis - Frequently Asked Questions Should I buy or sell Alector stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALEC shares. View ALEC analyst ratings or view top-rated stocks. What is Alector's stock price target for 2024? 7 Wall Street research analysts have issued 12-month price targets for Alector's shares. Their ALEC share price targets range from $4.00 to $35.00. On average, they predict the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 165.2% from the stock's current price. View analysts price targets for ALEC or view top-rated stocks among Wall Street analysts. How have ALEC shares performed in 2024? Alector's stock was trading at $7.98 at the start of the year. Since then, ALEC shares have decreased by 33.8% and is now trading at $5.28. View the best growth stocks for 2024 here. When is Alector's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our ALEC earnings forecast. How were Alector's earnings last quarter? Alector, Inc. (NASDAQ:ALEC) announced its earnings results on Tuesday, February, 27th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.80) by $0.31. The firm earned $15.19 million during the quarter, compared to analysts' expectations of $8.35 million. Alector had a negative trailing twelve-month return on equity of 71.80% and a negative net margin of 125.11%. What ETF holds Alector's stock? iShares Neuroscience and Healthcare ETF holds 5,088 shares of ALEC stock, representing 0.74% of its portfolio. What guidance has Alector issued on next quarter's earnings? Alector updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $60.0 million-$70.0 million, compared to the consensus revenue estimate of $100.9 million. What is Arnon Rosenthal's approval rating as Alector's CEO? 4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alector own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO). When did Alector IPO? Alector (ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO. Who are Alector's major shareholders? Alector's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.10%), Acadian Asset Management LLC (0.46%), Baillie Gifford & Co. (0.33%), Swiss National Bank (0.14%), Susquehanna Fundamental Investments LLC (0.13%) and Russell Investments Group Ltd. (0.08%). Insiders that own company stock include Arnon Rosenthal, Calvin Yu, Gary Romano, Marc Grasso, Polaris Venture Management Co, Richard H Scheller, Robert King, Robert Paul, Sara Kenkare-Mitra and Shehnaaz Suliman. View institutional ownership trends. How do I buy shares of Alector? Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Alector have any subsidiaries? The following companies are subsidiares of Alector: Alector LLC.Read More This page (NASDAQ:ALEC) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldThis 1 Biotech Stock has been shocking the marketsHuge AlertsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
